Skip to main content

Newest resources


Recommended actions for advocates to advance DMPA-SC

This DMPA-SC Advocacy Pack brief provides examples of actions that may be useful for advocates seeking to increase access to DMPA-SC, including self-injection.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

DMPA-SC key facts: Answering questions and dispelling common myths

This DMPA-SC Advocacy Pack brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Slide template: Expanding options and access with DMPA-SC

This customizable slide deck template from the DMPA-SC Advocacy Pack provides a brief description of DMPA-SC and its benefits; an overview of evidence on how the product expands access through multiple delivery channels; and illustrative policy and advocacy gaps and recommendations for country decision-makers. Available in PowerPoint and PDF formats.

Institutional author(s): PATH
Publication date: 2023

Policy brief template: Scaling-up self-injection of DMPA-SC to increase contraceptive access and options

This customizable DMPA-SC Advocacy Pack template provides a brief description of DMPA-SC; an overview of evidence on how the product expands access through multiple delivery channels; and policy and advocacy recommendations for country decision-makers.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Important policies for advancing access to DMPA-SC, including self-injection

This DMPA-SC Advocacy Pack brief offers an overview of key policies that affect introduction and scale-up of injectable contraceptives, including DMPA-SC.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Advocacy strategy development template: Planning to achieve DMPA-SC policy change, including self-injection

This DMPA-SC Advocacy Pack template includes a framework that supports individuals and organizations to develop a high-impact, outcome-oriented policy advocacy strategy. The template is available as a Word file in order to be customized for your context.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Increasing access to DMPA-SC in Uganda: An advocacy case study

This DMPA-SC Advocacy Pack brief describes key evidence-building efforts, advocacy actions, and policy changes in Uganda brought about by key partners to increase access to injectable contraception, including DMPA-SC. You can draw on lessons learned from Uganda to inform your policy goals and advocacy strategy for increasing method choice and access with DMPA-SC and self-injection in your country.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

DMPA and HIV: What advocates need to know

This DMPA-SC Advocacy Pack brief summarizes important takeaways for advocates based on World Health Organization guidance on hormonal contraception, including DMPA injectables, and HIV for women at high risk of HIV.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Balancing act: New developments and tensions in private sector access to DMPA-SC and self-injection

The Injectables Access Collaborative Learning and Action Network, in collaboration with USAID’s Frontier Health Markets Engage project, hosted this December 7, 2023 webinar on the latest innovations, policy developments, and evidence on access to DMPA-SC and self-injection through private sector channels such as pharmacies, drug shops, and private clinics.

One-third of contraceptive users in low- and middle-income countries access their method from a private sector source. Momentum is growing to ensure that contraceptive injectables, including DMPA-SC/self-injection, are among the range of methods offered through private channels. Speakers shared the latest evidence regarding pharmacy and drug shop provision of DMPA-SC/self-injection, updates on the release of a generic product, reflections on packaging for the private sector, and tensions between equity and financial sustainability in a changing landscape for contraceptive procurement financing. Speakers and participants discussed innovations to improve private sector channel economics and advance both equity and sustainability.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI, Frontier Health Markets Engage
Publication date: December, 2023

Injectables Market Assessment & Recommendations Summary

This healthy markets framework assessment highlights market opportunities for intramuscular (IM) and subcutaneous (SC) injectables and makes several recommendations on how to sustain and expand access.

The three primary takeaways from the assessment are:

  1. The lack of funding for procurement remains the main barrier to meeting global demand for injectables. This is also limiting demand across SRH products in general.
  2. IM injectables still dominate the injectables market. Shipments of SC injectables have been relatively modest over the last few years, with evidence of challenges to fulfill country orders. An increase is projected in the demand for SC injectables over time with secure, diversified supply, particularly if the price premium of SC versus that of IM injectables is reduced. The arrival of a generic SC injectable could make a significant difference when it comes to pricing, however uncertainties remain as to whether SC injectables will be able to fully realize their potential.
  3. Structural problems such as the lack of provider capacity and supportive policies to enable access are hindering the growth of the market for SC injectables and require special attention.

Institutional author(s): Shaping Equitable Market Access for Reproductive Health (SEMA Reproductive Health)
Publication date: July, 2023

Report